RGNX
REGENXBIO Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.92
−3.04%Margins
Gross margin
54.2%
EBITDA margin
-79.7%
EBIT margin
-94.1%
Net margin
-112.6%
FCF margin
-143.1%
-273.7%
Return on equity
-50.8%
Return on assets
-116.7%
Return on invested capital
0.48x
Asset turnover
-$246.7M
Cash from operations
$1.60
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026